Key facts, as of
As of November 9, 2026, Biogen Inc. (BIIB) trades at $254.87, up 63.9% over the past year. Its 52-week range runs from $153.77 to $261.00; the price is 2.3% below that high. It is 46.9% below its all-time high of $480.18, reached in March 2015. Over the 10 years to the end of October 2026, with dividends reinvested, it returned −9.5%, against +316.3% for the S&P 500 (SPY). It sits 25.2% above its 200-day average of $203.59, and its 50-day average is above the 200-day too: an uptrend on both averages. Its 30-day volatility is 35.3% annualized, which we rate high risk. It has a trailing P/E of 110.3.
Cite: Portfolio Terminal, "Biogen Inc. (BIIB) stock analysis", 2026-11-09. https://portfolio-terminal.com/analyse/biib
Where it trades today
trading 94% of the way up its 52-week range
How the price has moved
How far it is from its record
Biogen Inc. (BIIB) is 46.9% below its all-time high of $480.18, reached in March 2015. Over the 10 years to the end of October 2026, with dividends reinvested, it returned −9.5%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- BIIB closes above its 50-day average ($230.73), and the 50-day sits above the 200-day ($203.59): on both averages the chart reads as an uptrend.
- At $254.87, BIIB is 2.3% below its 1-year high of $261.00, set on November 9, 2026, and 67.9% above its 1-year low of $151.83 (November 7, 2025).
- Over the past month BIIB rose 12.9%, from $225.71 to $254.87.
- BIIB trades at 110.3x its last twelve months of earnings and 15.7x the next twelve months' estimate, so analysts expect earnings 603.8% higher.
- Its P/E is 140.8% above the 45.8x median of the 3 other drug manufacturers—general companies we track (LLY, JNJ, ABBV).
- BIIB's 30-day volatility, 35.3% a year, works out to a typical daily move of about 2.2%.
- Yahoo Finance puts its beta at 0.09: over five years of monthly returns, BIIB moved about 0.09% for each 1% move of the S&P 500.
What would change the read
- A close under the 50-day average, $230.73 (−9.5% from the last close), would turn the read to a pullback; under the 200-day, $203.59 (−20.1%), the longer rise is in question.
- A close above $261.00 (+2.4%) would be a new 1-year high; below $151.83 (−40.4%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for BIIB, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under drug manufacturers—general among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for BIIB by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for BIIB. Last refresh: Nov 9, 2026, 9:37 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Drug Manufacturers—General.
What Biogen Inc. does
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat…
Employees
7,500
Industry
Drug Manufacturers - General
Headquarters
Cambridge, United States
What analysts expect
BIIB carries a buy consensus from 32 analysts, with an average price target of $268.26 versus $254.87 today (+5.3%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
BIIB generated $10.30B in trailing revenue (10.6% year over year), with a 3.4% net margin, and $808.12M of free cash flow, against $6.50B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $9.89B | $7.49B | $2.47B | $1.29B | $8.83 | $1.97B |
| 2024 | $9.68B | $7.37B | $2.28B | $1.63B | $11.21 | $2.52B |
| 2023 | $9.84B | $7.30B | $1.85B | $1.16B | $8.02 | $1.24B |
| 2022 | $10.17B | $7.90B | $2.90B | $3.05B | $20.96 | $1.14B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
BIIB is in 15 of the 54 ETFs we track. It weighs most in XLV: 0.54% of the fund, holding #37 of 62.
How its figures compare with those peers
Companies in the same industry
BIIB beside the other companies Yahoo Finance files under drug manufacturers—general among the assets we track (LLY, JNJ, ABBV, largest first).
BIIByou are here$254.87$37.67B
LLYEli Lilly and Company$1411.95$1.26T
JNJJohnson & Johnson$282.11$679.13B
ABBVAbbVie Inc.$293.30$518.44BWhat the chart is saying
In an uptrend, 2.3% under its 1-year high with no resistance above.
uptrend- Price is 10.5% above its 50-day average and 25.2% above its 200-day.
- RSI at 62 is neither stretched nor washed out.
- Nothing above has stopped it this year; the nearest floor is $224.33 (-12.0%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is BIIB valued right now?
Biogen Inc. trades at 110.3 times its last twelve months of earnings and 15.7 times the next twelve months' estimate (Yahoo Finance, November 9, 2026). On the chart: in an uptrend, 2.3% under its 1-year high with no resistance above. Price is 10.5% above its 50-day average and 25.2% above its 200-day.
What is the risk level of BIIB?
Based on 30-day volatility of 35.3%, BIIB has HIGH risk. Its beta of 0.09 means it has swung less than the S&P 500 over the last five years.
Does BIIB pay dividends?
Yahoo Finance shows no dividend yield for Biogen Inc. (November 9, 2026).
How far is BIIB from its all-time high?
Biogen Inc. is 46.9% below its all-time high of $480.18, reached in March 2015. Over the 10 years to the end of October 2026, with dividends reinvested, it returned −9.5%, against +316.3% for the S&P 500 (SPY).
Which ETFs hold BIIB?
15 of the 54 popular ETFs we track hold Biogen Inc.. The largest weights: XLV (0.54%), VO (0.33%), RSP (0.22%), VTV (0.13%) and SPY (0.05%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is BIIB?
0.05%, as of September 30, 2026: BIIB is holding #283 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.51 in Biogen Inc..
What is the analyst price target for BIIB?
The average analyst price target for Biogen Inc. (BIIB) is $268.26 based on 32 analyst estimates, about 5.3% above the current price of $254.87. The published range runs from $175.00 to $350.00.
How much revenue does BIIB generate?
Biogen Inc. reported $10.30B in trailing twelve-month revenue. Revenue growth is running at 10.6% year over year. Net margin sits at 3.4%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare BIIB with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.